Table 1. Polymorphisms and the association with the response to chemotherapy and overall survival.

Polymorphism		No. of cases (%)a	Response to chemotherapy				Overall survival
			Responders (%)b	Nonresponders (%)b	OR (95% CI)c	P c	MST (95% CI)d	L-R-P	HR (95% CI)d	P d
RNF145 rs2043268
	AA	71 (27.6)	51 (71.8)	20 (28.2)	1.00		0.82 (0.64–1.09)	< 0.001	1.00
	AG	116 (45.2)	93 (80.2)	23 (19.8)	1.49 (0.71–3.12)	0.287	1.04 (0.88–1.14)		0.85 (0.60–1.20)	0.351
	GG	70 (27.2)	44 (62.9)	26 (37.1)	0.62 (0.29–1.33)	0.221	0.75 (0.53–0.85)		1.71 (1.18–2.50)	0.005
	Dominant				1.02 (0.53–1.96)	0.946		0.376	1.09 (0.80–1.49)	0.580
	Recessive				0.50 (0.26–0.94)	0.031		< 0.001	1.88 (1.38–2.57)	< 0.001
	Codominant				0.78 (0.52–1.15)	0.211			1.31 (1.07–1.60)	0.008
CINP rs762105
	AA	72 (28.5)	58 (80.6)	14 (19.4)	1.00		1.03 (0.82–1.25)	0.040	1.00
	AG	114 (45.0)	79 (69.3)	35 (30.7)	0.46 (0.21–0.99)	0.049	0.77 (0.66–0.89)		2.03 (1.43–2.88)	< 0.001
	GG	67 (26.5)	47 (70.2)	20 (29.9)	0.50 (0.21–1.18)	0.112	0.80 (0.67–0.97)		2.03 (1.38–2.99)	< 0.001
	Dominant				0.47 (0.23–0.99)	0.046		0.012	2.03 (1.47–2.82)	< 0.001
	Recessive				0.84 (0.44–1.61)	0.598		0.198	1.33 (0.98–1.81)	0.072
	Codominant				0.73 (0.49–1.09)	0.127			1.41 (1.17–1.69)	< 0.001

OR = odds ratio, CI = confidence interval, MST = median survival time (years), L-R-P = log-rank P, HR = hazard ratio, ECOG = Eastern Cooperative Oncology Group, NSE = neuron specific enolase.

^aColumn percentage.

^bRow percentage.

^cORs, 95% CI, and their corresponding P values were calculated by multivariate regression analysis, adjusted for age, gender, smoking status, stage, ECOG performance status, weight loss, NSE level, and first chemotherapy regimen.

^dHRs, 95% CI and their corresponding P values were calculated using multivariate Cox proportional hazard models, adjusted for age, gender, smoking status, stage, ECOG performance status, weight loss, NSE level, first chemotherapy regimen, 2nd line chemotherapy and radiation to primary tumor.